Literature DB >> 15563673

Role of p53, apoptosis, and cell proliferation in early stage Epstein-Barr virus positive and negative gastric carcinomas.

H H Ishii1, G C Gobe, J Yoneyama, M Mukaide, Y Ebihara.   

Abstract

AIMS: Mechanisms of Epstein-Barr virus (EBV) associated gastric tumour development are incompletely understood. The interrelations between EBV infection, apoptosis, cell proliferation, and the expression of the tumour suppressor gene p53 was investigated in 133 early stage gastric carcinomas.
METHODS: Tumour tissue was compared with paired non-tumour tissue. EBV encoded small RNAs (EBERs) determined EBV status. The apoptotic index (AI) was determined by morphology and verified biochemically. p53 and Ki-67 expression (cell proliferation) was assessed using immunohistochemistry.
RESULTS: EBV was detected in 14.3% of the cases. Cell proliferation did not differ significantly between EBV positive and negative cancers. However, within both these groups, the p53 positive and negative subsets differed significantly (EBV positive group: 76.8% and 55.3% were p53 positive or negative cancers, respectively; p<0.05; EBV negative group: 65.2% and 51.7% were p53 positive or negative, respectively; p<0.005). The numbers of p53 expressing EBV positive and negative cases were significantly different (57.9% and 82.5%, respectively; p<0.05). Compared with cell proliferation, apoptosis was significantly lower in EBV positive versus negative cancers (AI of 4.36 and 6.50, respectively; p<0.01). The p53 positive and negative subsets also differed significantly in AI (EBV positive group: AI of 5.13 and 3.30 for p53 positive and negative cancers, respectively; p<0.05: EBV negative group: AI of 6.84 and 4.90 for p53 positive and negative cancers, respectively; p<0.05).
CONCLUSIONS: These factors probably combine to promote development and progression of early stage gastric carcinomas and, at the same time, ensure the survival of EBV itself.

Entities:  

Mesh:

Year:  2004        PMID: 15563673      PMCID: PMC1770511          DOI: 10.1136/jcp.2003.015081

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  39 in total

1.  p53 inhibition by the LANA protein of KSHV protects against cell death.

Authors:  J Friborg; W Kong; M O Hottiger; G J Nabel
Journal:  Nature       Date:  1999 Dec 23-30       Impact factor: 49.962

2.  The K-bZIP protein from Kaposi's sarcoma-associated herpesvirus interacts with p53 and represses its transcriptional activity.

Authors:  J Park; T Seo; S Hwang; D Lee; Y Gwack; J Choe
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

3.  Relationship between expression of Bcl-2 genes and growth factors in ischemic acute renal failure in the rat.

Authors:  Glenda Gobé; Xiao-Ju Zhang; Desley A Willgoss; Estelle Schoch; Nicole A Hogg; Zoltán H Endre
Journal:  J Am Soc Nephrol       Date:  2000-03       Impact factor: 10.121

Review 4.  Anatomical methods in cell death.

Authors:  J F Kerr; G C Gobé; C M Winterford; B V Harmon
Journal:  Methods Cell Biol       Date:  1995       Impact factor: 1.441

5.  Oncogenic role of Epstein-Barr virus-encoded RNAs in Burkitt's lymphoma cell line Akata.

Authors:  J Komano; S Maruo; K Kurozumi; T Oda; K Takada
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

6.  Different roles of p53 between Epstein-Barr virus-positive and -negative gastric carcinomas of matched histology.

Authors:  Suzuko Moritani; Hiroyuki Sugihara; Ryoji Kushima; Takanori Hattori
Journal:  Virchows Arch       Date:  2001-11-23       Impact factor: 4.064

7.  New aspects in clinicopathologic and oncogene studies of 23 pulmonary lymphoepithelioma-like carcinomas.

Authors:  Yih-Leong Chang; Chen-Tu Wu; Jin-Yuan Shih; Yung-Chie Lee
Journal:  Am J Surg Pathol       Date:  2002-06       Impact factor: 6.394

8.  Epstein-Barr virus infection is an early event in gastric carcinogenesis and is independent of bcl-2 expression and p53 accumulation.

Authors:  M L Gulley; D R Pulitzer; P A Eagan; B G Schneider
Journal:  Hum Pathol       Date:  1996-01       Impact factor: 3.466

9.  Burkitt's lymphoma cells are resistant to programmed cell death in the presence of the Epstein-Barr virus latent antigen EBNA-4.

Authors:  S L Silins; T B Sculley
Journal:  Int J Cancer       Date:  1995-01-03       Impact factor: 7.396

Review 10.  p53 and human cancers.

Authors:  D P Lane
Journal:  Br Med Bull       Date:  1994-07       Impact factor: 4.291

View more
  6 in total

1.  Differential expression of apoptosis related proteins and nitric oxide synthases in Epstein Barr associated gastric carcinomas.

Authors:  Maria D Begnami; Andre L Montagnini; Andre L Vettore; Sueli Nonogaki; Mariana Brait; Alex Y Simoes-Sato; Andrea Q A Seixas; Fernando A Soares
Journal:  World J Gastroenterol       Date:  2006-08-21       Impact factor: 5.742

2.  EBV-infection in cardiac and non-cardiac gastric adenocarcinomas is associated with promoter methylation of p16, p14 and APC, but not hMLH1.

Authors:  Helene Geddert; Axel zur Hausen; Helmut E Gabbert; Mario Sarbia
Journal:  Cell Oncol (Dordr)       Date:  2011-05-03       Impact factor: 6.730

Review 3.  Epstein-Barr Virus and Gastric Cancer Risk: A Meta-analysis With Meta-regression of Case-control Studies.

Authors:  Jong-Myon Bae; Eun Hee Kim
Journal:  J Prev Med Public Health       Date:  2016-03-04

Review 4.  Epstein-Barr virus infection and gastric cancer: a systematic review.

Authors:  Xin-Zu Chen; Hongda Chen; Felipe A Castro; Jian-Kun Hu; Hermann Brenner
Journal:  Medicine (Baltimore)       Date:  2015-05       Impact factor: 1.889

5.  Association between Epstein-Barr virus infection and gastric cancer: a systematic review and meta-analysis.

Authors:  Ahmad Tavakoli; Seyed Hamidreza Monavari; Farid Solaymani Mohammadi; Seyed Jalal Kiani; Saber Armat; Mohammad Farahmand
Journal:  BMC Cancer       Date:  2020-06-01       Impact factor: 4.430

Review 6.  Epstein-Barr Virus Epithelial Cancers-A Comprehensive Understanding to Drive Novel Therapies.

Authors:  Shuting Han; Joshua K Tay; Celestine Jia Ling Loh; Axel Jun Ming Chu; Joe Poh Sheng Yeong; Chwee Ming Lim; Han Chong Toh
Journal:  Front Immunol       Date:  2021-12-10       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.